News for Poxel S.A. (POXEL.PA)

Sep 26, 2023 / 12:30PM GMTAurélie Bozza - Hello, everyone, and welcome to this live webcast on the occasion of the release of the half year financial result

Mar 23, 2023 / 01:45PM GMTOperator (technical difficulty) (Operator Instructions) I now hand over to Thomas.Thomas Kuhn - Poxel S.A. - Co-Founder, CEO & Directo

Sep 21, 2022 / 12:45PM GMTOperator Hello, everyone, and welcome to this webinar focused on Poxel 2022 half-year results and the review of DESTINY-1 full year re

Mar 22, 2022 / 06:00PM GMTOperator This meeting is being (technical difficulty)Unidentified Company Representative - (technical difficulty) communication of an

Sep 23, 2021 / 05:00PM GMTOperator Hello, everyone. Welcome to Poxel's Half Year 2021 Results Presentation. (Operator Instructions) Thomas, I give you the floor

Jul 12, 2021 / 05:15PM GMTThomas Kuhn - Poxel S.A. - Co-Founder, CEO & Director Thank you for joining us today. I'm Thomas Kuhn. I'm the CEO of Poxel. You can s

Dec 14, 2020 / 01:30PM GMTOperator Welcome to the Poxel KOL Investor Event Conference Call. My name is John, and I'll be your operator for today's call. (Operat

Sep 15, 2020 / 05:30PM GMTOperator Ladies and gentlemen, welcome to the Poxel Half Year Results 2020 Conference Call. I'll now hand the call over to Madame Jona

Seasoned Biotechnology and Corporate Management Experts, Khoso Baluch, Jeffrey Pfeffer, and Wa’el Hashad, Elected to Board at Annual Meeting of...

Poxel S.A. press release (PXXLF): 1H net result for the financial period ending June 30, 2022, was a net loss of €13.4M, as compared to a net loss of €8.0M in the corresponding period...

POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disord...

POXEL SA , a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis , today announced that,... | January 14, 2021

POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disord...

POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including

POXEL SA , a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis , today announced its... | January 5, 2021